Get the Stockscreener App
32.60
1.27%
0.41
After Hours:
32.73
0.13
+0.40%
Royalty Pharma Plc stock is traded at $32.60, with a volume of 2.54M.
It is up +1.27% in the last 24 hours and down -1.27% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$32.19
Open:
$32.09
24h Volume:
2.54M
Relative Volume:
0.56
Market Cap:
$14.00B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
12.78
EPS:
2.55
Net Cash Flow:
$2.80B
1W Performance:
+4.45%
1M Performance:
-1.27%
6M Performance:
+16.22%
1Y Performance:
+18.07%
1-Day Range:
$32.09
$32.66
1-Week Range:
$30.96
$32.66
52-Week Range:
$24.05
$34.20
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.60 | 14.00B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Portolan Capital Management LLC Has $8.78 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Evergreen Capital Management LLC - MarketBeat
Regal Investment Advisors LLC Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Ontario Teachers Pension Plan Board Sells 10,748 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Sterling Capital Management LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Treasurer of the State of North Carolina Sells 10,837 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
Royalty Pharma plc to Announce Q1 2025 Financial Results on May 8, 2025 - Nasdaq
Royalty Pharma Schedules Critical Q1 2025 Earnings Release: Key Details for Investors - Stock Titan
Legal & General Group Plc Has $67.19 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
APG Asset Management N.V. Grows Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Aviva PLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
CenterBook Partners LP Sells 113,525 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
APG Asset Management US Inc. Buys Shares of 7,872 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Fmr LLC - MarketBeat
Russell Investments Group Ltd. Buys 449,551 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
ADAR1 Capital Management LLC Sells 1,046,703 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Franklin Resources Inc. Sells 921,034 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
JPMorgan Chase & Co. Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma modifies acquisition agreement By Investing.com - Investing.com South Africa
Royalty Pharma modifies acquisition agreement - Investing.com
ExodusPoint Capital Management LP Invests $3.66 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Prudential PLC - MarketBeat
Headlands Technologies LLC Has $115,000 Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Geode Capital Management LLC Grows Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To Know - Yahoo Finance
15,300 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Integrated Quantitative Investments LLC - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Position Cut by Rhenman & Partners Asset Management AB - MarketBeat
Royalty Pharma Enters Oversold Territory - Nasdaq
Arrowstreet Capital Limited Partnership Sells 720,342 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Sei Investments Co. - MarketBeat
Royalty Pharma Appoints Vlad Coric to Board of Directors - citybiz
Royalty Pharma expands board with Biohaven CEO appointment By Investing.com - Investing.com South Africa
Royalty Pharma expands board with Biohaven CEO appointment - Investing.com Australia
Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors - The Manila Times
Biotech Leader Behind $13B Pfizer-Biohaven Deal Takes Strategic Role at Royalty Pharma - Stock Titan
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Alliancebernstein L.P. - MarketBeat
Schroder Investment Management Group Sells 354,483 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):